Alphs, L, Benson, C, Cheshire-Kinney, K, Lindenmayer, J-P, Mao, L, Rodriguez, SC and Starr, HL (2015) Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia. Journal of Clinical Psychiatry 1, 554–561.
Alphs, L, Bossie, CA, Sliwa, JK, Ma, Y-W and Turner, N (2011) Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. Annals of General Psychiatry 10 (1), 12.
Ascher-Svanum, H, Peng, X, Faries, D, Montgomery, W and Haddad, PM (2009) Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients. BMC Psychiatry 9, 46.
Attard, A, Olofinjana, O, Cornelius, V, Curtis, V and Taylor, D (2014) Paliperidone palmitate long-acting injection--prospective year-long follow-up of use in clinical practice. Acta Psychiatrica Scandinavica 130, 46–51.
Barnes, TRE (2005) Why indeed?: Invited commentary on… Why aren't depot antipsychotics prescribed more often and what can be done about it? Advances in Psychiatric Treatment 11, 211–213.
Berwaerts, J, Liu, Y, Gopal, S, Nuamah, I, Xu, H, Savitz, A, Coppola, D, Schotte, A, Remmerie, B, Maruta, N and Hough, DW (2015) Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia. JAMA Psychiatry 72, 830.
Bosanac, P and Castle, D (2015) Why are long-acting injectable antipsychotics still underused?. Advances in Psychiatric Treatment 21, 98–105.
Brissos, S, Veguilla, MR, Taylor, D and Balanzá-Martinez, V (2014) The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Therapeutic Advances in Psychopharmacology 4, 198–219.
Coppola, D, Liu, Y, Gopal, S, Remmerie, B, Samtani, MN, Hough, DW, Nuamah, I, Sulaiman, A and Pandina, G (2012) A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. BMC Psychiatry 12, 26.
Decuypere, F, Sermon, J, Geerts, P, Denee, TR, De Vos, C, Malfait, B, Lamotte, M and Mulder, CL (2017) Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: a retrospective database study. PLoS ONE 12, e0179049.
Fleischhacker, WW, Gopal, S, Lane, R, Gassmann-Mayer, C, Lim, P, Hough, D, Remmerie, B and Eerdekens, M (2012) A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. International Journal of Neuropsychopharmacology 15, 107–118.
Furukawa, TA, Levine, SZ, Tanaka, S, Goldberg, Y, Samara, M, Davis, JM, Cipriani, A and Leucht, S (2015) Initial severity of schizophrenia and efficacy of antipsychotics. JAMA Psychiatry 72, 14.
Haddad, PM, Kishimoto, T, Correll, CU and Kane, JM (2015) Ambiguous findings concerning potential advantages of depot antipsychotics. Current Opinion in Psychiatry 28, 216–221.
Health and Social Care Information Centre (2016) Prescription Cost Analysis, England - 2015, NHS Digital.
Hough, D, Gopal, S, Vijapurkar, U, Lim, P, Morozova, M and Eerdekens, M (2010) Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophrenia Research 116, 107–117.
Johnson, DAW (2009) Historical perspective on antipsychotic long-acting injections. British Journal of Psychiatry 195, 7–13.
Kirson, NY, Weiden, PJ, Yermakov, S, Huang, W, Samuelson, T, Offord, SJ, Greenberg, PE and Wong, BJO (2013) Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. Journal of Clinical Psychiatry 74, 568–575.
Kishimoto, T, Nitta, M, Borenstein, M, Kane, JM and Correll, CU (2013) Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. Journal of Clinical Psychiatry 74, 957–965.
Kishimoto, T, Robenzadeh, A, Leucht, C, Leucht, S, Watanabe, K, Mimura, M, Borenstein, M, Kane, JM and Correll, CU (2014) Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophrenia Bulletin 40, 192–213.
Kozma, CM, Slaton, T, Dirani, R, Fastenau, J, Gopal, S and Hough, D (2011) Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE). Current Medical Research and Opinion 27, 1603–1611.
Kramer, M, Litman, R, Hough, D, Lane, R, Lim, P, Liu, Y and Eerdekens, M (2010) Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. The International Journal of Neuropsychopharmacology 13, 635–647.
Kramer, M, Simpson, G, Maciulis, V, Kushner, S, Vijapurkar, U, Lim, P and Eerdekens, M (2007) Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia. Journal of Clinical Psychopharmacology 27, 6–14.
Leucht, C, Heres, S, Kane, JM, Kissling, W, Davis, JM and Leucht, S (2011) Oral versus depot antipsychotic drugs for schizophrenia-A critical systematic review and meta-analysis of randomised long-term trials. Schizophrenia Research 127, 83–92.
Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C and Davis, JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. The Lancet 373, 31–41.
Li, H, Rui, Q, Ning, X, Xu, H and Gu, N (2011) A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35, 1002–1008.
Marcus, SC, Zummo, J, Pettit, AR, Stoddard, J and Doshi, JA (2015) Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. Journal of Managed Care & Specialty Pharmacy 21, 754–769.
Markowitz, M, Fu, D-J, Levitan, B, Gopal, S, Turkoz, I and Alphs, L (2013) Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies. Annals of General Psychiatry 12, 22.
McCrone, P, Dhanasiri, S, Patel, A, Knapp, M and Lawton-Smith, S (2008) Paying the Price: The Cost of Mental Health Care in England to 2026. The King's Fund.
McEvoy, JP, Byerly, M, Hamer, RM, Dominik, R, Swartz, MS, Rosenheck, RA, Ray, N, Lamberti, JS, Buckley, PF, Wilkins, TM and Stroup, TS (2014) Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia. Journal of the American Medical Association 311, 1978.
Mehnert, A, Nicholl, D, Pudas, H, Martin, M and McGuire, A (2012) Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. Journal of Medical Economics 15, 844–861.
Muser, E, Kozma, CM, Benson, CJ, Mao, L, Starr, HL, Alphs, L and Fastenau, J (2015) Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement. Journal of Medical Economics 18, 637–645.
Naber, D, Hansen, K, Forray, C, Baker, RA, Sapin, C, Beillat, M, Peters-Strickland, T, Nylander, AG, Hertel, P, Andersen, HS, Eramo, A, Loze, JY and Potkin, SG (2015) Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophrenia Research 168, 498–504.
Pandina, G, Lane, R, Gopal, S, Gassmann-Mayer, C, Hough, D, Remmerie, B and Simpson, G (2011) A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Neuro-Psychopharmacology & Biological Psychiatry 35, 218–226.
Patel, R, Chesney, E, Cullen, AE, Tulloch, AD, Broadbent, M, Stewart, R and McGuire, P (2016a) Clinical outcomes and mortality associated with weekend admission to psychiatric hospital. British Journal of Psychiatry 209, 29–34.
Patel, R, Jayatilleke, N, Broadbent, M, Chang, C-K, Foskett, N, Gorrell, G, Hayes, RD, Jackson, R, Johnston, C, Shetty, H, Roberts, A, McGuire, P and Stewart, R (2015a) Negative symptoms in schizophrenia: a study in a large clinical sample of patients using a novel automated method. BMJ Open 5, 1–9, e007619.
Patel, R, Lloyd, T, Jackson, R, Ball, M, Shetty, H, Broadbent, M, Geddes, JR, Stewart, R, McGuire, P and Taylor, M (2015b) Mood instability is a common feature of mental health disorders and is associated with poor clinical outcomes. BMJ Open 5, 1–9, e007504.
Patel, R, Reiss, P, Shetty, H, Broadbent, M, Stewart, R, McGuire, P and Taylor, M (2015c) Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study. BMJ Open 5, 1–6, e008341.
Patel, R, Shetty, H, Jackson, R, Broadbent, M, Stewart, R, Boydell, J, McGuire, P and Taylor, M (2015d) Delays before diagnosis and initiation of treatment in patients presenting to mental health services with bipolar disorder. PLoS ONE 10, 1-17, e0126530.
Patel, R, Wilson, R, Jackson, R, Ball, M, Shetty, H, Broadbent, M, Stewart, R, McGuire, P and Bhattacharyya, S (2016b) Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study. BMJ Open 6, 1–9, e009888.
Pinto, R, Ashworth, M, Seed, P, Rowlands, G, Schofield, P and Jones, R (2010) Differences in the primary care management of patients with psychosis from two ethnic groups: a population-based cross-sectional study. Family Practice 27, 439–446.
Savitz, AJ, Xu, H, Gopal, S, Nuamah, I, Ravenstijn, P, Janik, A, Schotte, A, Hough, D and Fleischhacker, WW (2016) Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. International Journal of Neuropsychopharmacology 19, pyw018.
Schreiner, A, Aadamsoo, K, Altamura, AC, Franco, M, Gorwood, P, Neznanov, NG, Schronen, J, Ucok, A, Zink, M, Janik, A, Cherubin, P, Lahaye, M and Hargarter, L (2015) Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophrenia Research 169, 393–399.
Taylor, D and Olofinjana, O (2014) Long-acting paliperidone palmitate – interim results of an observational study of its effect on hospitalization. International Clinical Psychopharmacology 29, 229–234.
Taylor, DM, Fischetti, C, Sparshatt, A, Thomas, A, Bishara, D and Cornelius, V (2009) Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. Journal of Clinical Psychiatry 70, 196–200.
Tiihonen, J, Haukka, J, Taylor, M, Haddad, PM, Patel, MX and Korhonen, P (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. American Journal of Psychiatry 168, 603–609.
Voss, EA, Ryan, PB, Stang, PE, Hough, D and Alphs, L (2015) Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics. International Clinical Psychopharmacology 30, 151–157.
Zeidler, J, Mahlich, J, Greiner, W and Heres, S (2013) Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany. Applied Health Economics and Health Policy 11, 509–521.